Antiplatelet treatment and gastro-intestinal hemorrhage risk
Ratio of atherothrombotic risk and risk of hemorrhage complications should be estimated before aspirin prescription as a component of cardiovascular event prevention. It is unlikely that there exists a daily aspirin dose, possessing antiplatelet efficacy, but without gastro-intestinal (GI) hemorrhag...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2005-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/995 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Ratio of atherothrombotic risk and risk of hemorrhage complications should be estimated before aspirin prescription as a component of cardiovascular event prevention. It is unlikely that there exists a daily aspirin dose, possessing antiplatelet efficacy, but without gastro-intestinal (GI) hemorrhage risk. Data of large-scale randomized trails have demonstrated the benefits of clopidogrel, with fewer adverse effects and better tolerability. According to CAPRIE trail results, clopidogrel should be prescribed to high-risk patients unable to take aspirin. It is recommended to use only minimal effective aspirin doses in combination with clopidogrel. The strategy of GI protection with proton pump inhibitors and/or H. pylori eradication for aspirin-taking patients at high risk of GI bleeding is widely discussed in literature. Up to now, there is little evidence supporting this strategy that is most important for life-long protection against atherothrombotic events. |
|---|---|
| ISSN: | 1728-8800 2619-0125 |